36 search results for: quality of life

Why did the definition <b>of</b> control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of chronic obstructive pulmonary disease (COPD).

expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

45 min

Pulmonology

Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

ERS 2024 | Understanding the Complex Pathophysiology <b>of</b> COPD

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

How Can We Explore the Concept <b>of</b> Disease Modification in Children With AD?

expert video

How Can We Explore the Concept of Disease Modification in Children With AD?

2 min

Dermatology

Dr. Lawrence Eichenfield discusses the concept of disease modification in children with AD.

New Perspectives in Understanding Pathophysiology <b>of</b> Atopic Dermatitis in Children

expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

12 min

Dermatology

Dr. Stephan Weidinger describes the roles of IL-4 and IL-13 in skin barrier dysfunction, and the potential of early control of type 2 inflammation to modify disease course. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.

ERS 2024 | Unraveling the Role <b>of</b> Type 2 Inflammation in COPD

expert video

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

8 min

Pulmonology

Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.

The Multidimensional Impact <b>of</b> Atopic Dermatitis on Children and Their Caregivers

expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

1 min

Dermatology

Discover the multidimensional impact of pediatric atopic dermatitis on children and caregivers – a soundbite from the Expert Lounge Canada 2022.

Importance <b>of</b> Lung Function Assessment in Pediatric Asthma Patients

videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in pediatric patients with severe asthma, and the value of clinical lung function assessments.

Role <b>of</b> Type 2 Inflammation Across Different Chronic Diseases

expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

36 min

Type 2 Inflammation

Profs. Oscar Palomares, Stephan Weidinger, Valerie Lund, and Ulrike von Arnim highlight how underlying type 2 inflammation contributes to key symptoms of inflammatory diseases across organs

The Relationship Between Skin Barrier Dysfunction and Increased Risk <b>of</b> Allergen Sensitization in AD

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region